Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Moodys
Johnson and Johnson
Dow
Colorcon

Last Updated: August 10, 2022

CLINICAL TRIALS PROFILE FOR IVACAFTOR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ivacaftor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00457821 ↗ Safety Study of Ivacaftor in Subjects With Cystic Fibrosis Completed Cystic Fibrosis Foundation Phase 2 2007-05-01 The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
NCT00457821 ↗ Safety Study of Ivacaftor in Subjects With Cystic Fibrosis Completed Cystic Fibrosis Foundation Therapeutics Phase 2 2007-05-01 The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
NCT00457821 ↗ Safety Study of Ivacaftor in Subjects With Cystic Fibrosis Completed Vertex Pharmaceuticals Incorporated Phase 2 2007-05-01 The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
NCT00909532 ↗ Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation Completed Cystic Fibrosis Foundation Phase 3 2009-06-01 The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
NCT00909532 ↗ Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation Completed Cystic Fibrosis Foundation Therapeutics Phase 3 2009-06-01 The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ivacaftor

Condition Name

Condition Name for Ivacaftor
Intervention Trials
Cystic Fibrosis 108
Chronic Obstructive Pulmonary Disease 3
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation 2
Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ivacaftor
Intervention Trials
Cystic Fibrosis 111
Fibrosis 103
Lung Diseases 5
Pulmonary Disease, Chronic Obstructive 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ivacaftor

Trials by Country

Trials by Country for Ivacaftor
Location Trials
Canada 95
United Kingdom 83
Australia 65
Germany 61
France 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ivacaftor
Location Trials
Massachusetts 55
California 53
Missouri 52
Ohio 51
Pennsylvania 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ivacaftor

Clinical Trial Phase

Clinical Trial Phase for Ivacaftor
Clinical Trial Phase Trials
Phase 4 12
Phase 3 58
Phase 2/Phase 3 1
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ivacaftor
Clinical Trial Phase Trials
Completed 75
Recruiting 16
Active, not recruiting 12
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ivacaftor

Sponsor Name

Sponsor Name for Ivacaftor
Sponsor Trials
Vertex Pharmaceuticals Incorporated 92
Cystic Fibrosis Foundation 14
Cystic Fibrosis Foundation Therapeutics 13
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ivacaftor
Sponsor Trials
Industry 102
Other 73
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKinsey
Medtronic
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.